Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BIBF 1120 versus sunitinib in previously untreated renal cell cancer
2009-009516-44Phase 2Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Sep 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in renal cell carcinoma (RCC) comparing BIBF 1120 with sunitinib (2 arms). Primary endpoint: Progression-free survival. Started Sep 2009; status: completed.
02
Drugs
nintedanibsunitinib
03
Conditions
renal cell carcinoma (RCC)
Beyond the preview
Go deeper on 2009-009516-44.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-009516-44.